Back to top

Analyst Blog

IDE Submitted Seeking Approval of U.S. Feasibility Study


 ZacksTrade Now

IDE Submitted Seeking Approval of U.S. Feasibility Study

By Brian Marckx, CFA

This morning Aethlon Medical (OTC BB:(AEMD)) announced that they have submitted an Investigational Device Exemption (IDE) to the FDA seeking approval to commence a 10-patient safety and effectiveness feasibility study of Hemopurifier.  We view this as a meaningful step towards AEMD's goal of bringing Hemopurifier to the U.S. market.  The company notes that data from the recent and ongoing studies at hospitals in India were used to support the IDE submission and also included HCV capture data, the latter which that the FDA had requested at a pre-IDE meeting in 2011.

The proposed trial, which we expect would begin shortly following an approval by FDA of the IDE, would enroll 10 end stage renal disease patients infected with HCV and be conducted by the Renal Research Institute, a partnership between Fresenius Medical Care (FMS), a leader in dialysis products and services, and Beth Israel Medical Center in NYC.

Click here to view our most recent report on AEMD.


About Renal Research Institute*

Renal Research Institute (RRI) was established in 1997 as a partnership between Fresenius Medical Care (FMC) and Beth Israel Medical Center, New York City. It is an administratively distinct institution which collaborates with a select group of US based dialysis facilities with strong ties to academic research including the University of Michigan, the University of North Carolina, the University of Rochester, Yale University through St. Raphael Hospital in New Haven, CT and their dialysis facilities. RRI trains Research fellows from countries around the world in kidney disease-related clinical research. Its research spans a full spectrum of interests from molecular biology, clinical research, and pharmaceutical trials to epidemiology. The network of international collaborators has made it a global research institution with ties to Europe, Asia, Central and South America and Africa. The Institute is dedicated to improving the outcomes of patients with kidney disease requiring dialysis. RRI members participated in the NIH funded, NCDS, HEMO, CHOICE and FHN trials.

 *SOURCE: Renal Research Institute

For additional research on small-cap stocks, please visit

To become a subscriber to Zacks SCR and receive SCR blogs and research reports emailed directly to your inbox, please visit our Subscribe page.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%